Trying to find an answer to the Amgen / GDNF debate...
SHOULD HUMANS SUFFER NEEDLESSLY?

this ticks me off -
someone at Amgen needs to have their feet held to the fire...

http://www.wma.net/e/policy/b3.htm
- The Helsinki Declaration
The World Medical Association has developed the Declaration of Helsinki as a statement of ethical principles to provide guidance to physicians and other participants in medical research involving human subjects. Medical research involving human subjects includes research on identifiable human material or identifiable data.


sincerely,
CTenaLouise

Sci Eng Ethics. 2006 Jan;12(1):131-8. Related Articles, Links The protection of patients' rights in clinical trials.

Czarkowski M.

Department of Internal Medicine and Endocrinology, Medical University of Warsaw, ul. Banacha 1A, 02-097 Warsaw, Poland.
mczark@amwaw.edu.pl

The Helsinki Declaration is a very important document regarding the protection of patients' rights in clinical trials and one of the fundamental sources of operational principles for every ethics committee.

Although they have been updated, the international guidelines for ethics committees continually fail to address certain issues pertaining to the protection of patients' rights in clinical trials. These issues include, most significantly, the method of electing ethics committees (a free, secret ballot should be preferred to direct appointment), the avoidance of conflict of interest during the election of ethics committee members, and the necessary insurance coverage for the participants of clinical trials. Polish law should, on the other hand, be developed in such way as to not limit the effectiveness of ethics committees in protecting patients' rights in clinical trials. The ideal solution would be to draft a uniform law concerning not only clinical trials, but all medical experiments. The opinions of experts who have been reviewing medical research projects for several years may prove to be especially valuable in this setting.

PMID: 16501654 [PubMed - indexed for MEDLINE]

http://www.bio-itworld.com/newsitems...ws?page:int=-1







Skip to content.
Bio-IT World On-Demand: White Papers
Visit our white paper library often
to understand more about key
technology issues in bio-IT today

Call for Speakers!
Now accepting speaking
proposals for next
year's conference


BUSINESS+STRATEGY
News & Opinion
Regulatory Policy
Finance & Markets
Company Strategies
People
Product Info
SCIENCE+TECHNOLOGY
News & Opinion
Drug Discovery
Genomics
Proteomics
Lab Equipment & LIMS
Systems Biology
Product Info
IT+INFORMATICS
News & Opinion
IT Infrastructure
Informatics Tools & Data
High-Performance Computing
Knowledge Management & Collaboration
Clinical Trials Research
Product Info
PRODUCT INFO
HEALTH-IT WORLD
SUBSCRIBE
ADVERTISE
Download Media Kit
Editorial Calendar
Circulation
Web
E-Newsletters
Webcasts
Print
Events
List Rental
Reprints
Life Sciences Conference + Expo
Contacts
Events | Awards | Archives | White papers | Feeds | Link to Us | About Us Search sponsored by
Phoenix Data Systems Site Search Web
powered by Vivisimo Velocity
Personal toolsYou are not logged in Log in
October 06, 2006 | Home > News > 2005 > March >
At Clinical Trials Congress, News About Industry-Run Trial Registries By Mark D. Uehling, BIO-IT World
March 02, 2005 | (03/02/05)—The 2005 Clinical Trial Congress explored what may be the most private area of any pharmaceutical company's anatomy. That would be its unpublished clinical trials. Must the pharmaceutical industry reveal more? Or should it ride out the cries of journal editors who demand that it disclose the designs and results of trials? That question will roil government regulators, journal editors, and companies of all sizes this year.


As the meeting in Philadelphia last week made clear, most companies now elect to publish clinical trial data only when those facts can be used in advertising and marketing. The vast majority of clinical trials are consigned to a dusty file cabinet or perhaps read by a regulatory official -- and then consigned to a dusty file cabinet.

In a panel on trial registries at the Clinical Trials Congress conference, it was clear some of the thought leaders in the industry do not fear more disclosure of unpublished trials per se. They're already undertaking the selective dissemination of trial designs both via their own websites and the federal government.

What does concern some of the leading companies is a proliferation of clinical trial registries around the world. To head that off, physicians from two major companies -- Eli Lilly and GlaxoSmithKline (GSK) -- took the Philadelphia podium and explained their efforts to date. A third company doctor, from Merck, offered his sympathy but explained his employer's strategy, which is more synchronized with that of the industry as a whole.

Ronald Krall, senior VP of worldwide development at Glaxo, began by showing a slide of nasty, negative headlines about the industry in the news media. "It took me about five minutes to find these," Krall began. He said there are two intertwined crises of confidence, one in the industry in general, and another for the clinical trial endeavor in particular. In one poll, he noted, "60 percent of the people were not very or not at all sure that drug companies publish timely information on side effects. As the respondents were older, the doubts were higher. Yet they are the ones that use more of the drugs that we produce."

Clearly, Krall said, confidence in the industry is in short supply at the moment, despite the precaution and thought that goes into clinical research. Glaxo has launched an online database of its clinical trials to begin to restore that confidence.

Taking such a route was much debated inside GSK, Krall suggested. But at the end of the day, the company believed there was an implicit ethical contract with patients. Those who elect to participate in clinical trials, Krall said, "expect that the results of the trial in which they're participating will be available and contribute to the knowledge that informs medical practice. We actually have always had an obligation to make the results of trials known in an appropriate fashion. What we're facing today is a shift in the expectation of what's appropriate."

At GSK, he said, the company will publish most trials that meet nonbonding International Conference on Harmonization (ICH) guidelines about hypothesis-testing studies. The company will describe its finished Phase I-IV trials begun since 2000, though some trials prior to 2000 may also be included. Ongoing research is first deposited in ClinicalTrials.gov, an NIH effort with a tiny fraction of all industry-sponsored trials.

For tracking purposes, ClinicalTrials.gov will assign each trial a unique numerical identifier. The information to be published at the GSK website includes type of trial, rationale, methods, study design, patient population demographics, primary and secondary endpoints, adverse events, and references to published citations in the peer-reviewed medical literature. That's most of the laundry list of requests from editors of a handful of elite medical journals, who have made a so-far empty threat to block articles about trials that have not been put in a searchable public registry.

Needless to say, there is little agreement between what journal editors, trial sponsors, the ICH, and regulators believe should be included in an online registry of clinical trials. Much of the private bargaining seems to be turning on which database fields will need to be supplied by the industry.

For its part, GSK is choosing not to publish the results of a trial. It's unclear how the medical editors will respond to this. In some ways, a clinical trial registry without any results -- without stating if a drug worked or not -- is like a topless bar in which the entertainers remain clothed. There are other places (such as peer-reviewed journals and medical conferences) where trial results may be bared. But a no-results strategy could disappoint community and academic physicians attempting to advise their patients and move beyond the cursory information in either the scientific literature or the FDA-approved label.

Will Glaxo's approach be enough to silence the critics of the industry? It's not clear. Private discussions with top medical editors appear to be ongoing. Said Krall: "We think this is a viable solution. They are beginning to agree this is a very pragmatic solution. I’m hopeful we can reach an agreement."

His real worry, Krall confessed, is the proliferation of different regulatory obligations around the world. As it is, there are several dozen people working on this area in GSK. "The cost as long as it's one registry is pretty marginal," said Krall. "We really fear the proliferation of national registries. It could turn out to be a big burden on us."

Krall's presentation described Glaxo's sincere, well-conceived, and vigorous desire to meet the critics of the industry more than halfway. Its registry is, as much as anything, a testament to GSK's faith in its own scientific integrity and medical ethics. The company appears to have sufficient confidence in the primacy of its science to allow it to endure short-term pain that may accompany its registry.

Indeed, Krall has warned the company's high-level managers, lawyers, and communications specialists about a few bumps along the way. "As we populate registries, there is going to be information that wasn't available before," said Krall. "People are going to interpret it. We are going to take some hits for that, as individual companies and as an industry. We know it will happen. We are committed to driving forward despite the fact that we know it will happen."

That displayed a level of organizational bravery that, for now, only one company in the industry is willing to match. In another presentation at the Clinical Trials Congress, Eli Lilly's global medical director, Per Cantor, outlined that company's online registry. "What we are discussing today is only the first chapter," said Cantor.

At Lilly, Cantor said, there has been a philosophical shift about registering trials and publishing selective facts about them. "We had the philosophy of saying, 'Why disclose?' Is it needed that we share information that was traditionally considered confidential?" Cantor asked. "That has shifted to a consensus of, 'Why not disclose?'"

Rather than wait to be further pummeled by a skeptical public and a skittish regulatory community, Lilly decided to get out in front of a coming shift in the minimal level of disclosure about many routine trials. It too seems worried about registries multiplying like rabbits. "There are 300 registries right now," Cantor noted. "It’s very important that the industry takes the lead."

Cantor's explanation of exactly what is published at Lilly's site was not as explicit as the Glaxo presentation. "We will post [trials] within one year after the completion of the trial," said Cantor. "That's what we have concluded is an appropriate measure. There may be situations where we cannot meet the one-year deadline."

Cantor urged other companies in the industry to begin determining their own comfort level with greater disclosure. In many cases, it would appear, the confidence of Glaxo and Lilly make them outliers.

Merck, for example, spoke briefly in the same session in Philadelphia. Laurence Hirsch, Merck's executive director of medical communications, took pains to explain that his department only works with physicians to publish company-sponsored work in journals. It doesn't do marketing. Hirsch said Merck prefers to participate in a scientific dialogue with physicians using the peer-reviewed literature. "We do not have a Merck clinical trial registry," said Hirsch. "We don't have a trial results database on Merck.com. The company's thinking at this point is that it is not intending to go down that road."

In a sense, Merck believes the existing system of publishing clinical trials is meeting the needs of physicians. "If you talk to academics and journal editors," Hirsch said, "they will bring a great deal of skepticism and criticism to this. They will not necessarily accept it."

Hirsch seemed saddened and wearied by the perception of both his company and the industry as being inclined to manipulate unflattering trial data. "We have published more negative trials in the last decade than anybody," said Hirsch. "Some of these are large and important trials. They're there."








Email to a Friend Printer Friendly Order Reprints Related Stories
Researchers Identify a Key Regulator for Skin Stem Cells | October 06, 2006
Bio-IT World Call for Speakers | October 05, 2006
$10m Prize for Super Genetic Test | October 05, 2006
Plans Unveiled for State-Financed Stem Cell Work in California | October 05, 2006
PremPro Plaintiff Wins $1.5 Million in Damages Against Wyeth | October 05, 2006
$10 Million Prize Offered for Genome Sequencing | October 04, 2006
American Wins Nobel Chemistry Prize | October 04, 2006
Agency Agrees to Review Human Stem Cell Patents | October 04, 2006
U.S. to Stop Seizing Canadian Medicine | October 04, 2006
Craig C. Mello and Andrew Z. Fire Win 2006 Nobel Prize in Physiology or Medicine | October 03, 2006
New Web Tool May Speed Drug Discovery | October 03, 2006
Icahn, Seeking ImClone Control, Urges Push on Erbitux | October 02, 2006
Completion of Allen Brain Atlas Hailed as “Epoch-Making” | September 28, 2006
Analysis: Making Biotech Drugs Cheaper | September 28, 2006
Amgen Prices Colon Cancer Drug 20% Below ImClone Rival | September 28, 2006
Advertisement
Featured Webcast

More Webcasts >>
Latest E-Newsletters
Subscribe | Archives
archn_016.jpg
Best Practices
Improving Product Development and Lifecycle Management
Bio-IT World Live
Bio-IT World Live - March 13, 2006
Bio-IT World Weekly Update
Bio-IT World Weekly Update - March 14, 2006
Drug Discovery News
Drug Discovery News - Feb. 20, 2006
eCliniqua
SAS on Databases, Allergan on CTMS
Inside IT
Pfizer Data Mining Focuses on Clinical Trials
Microarray Technology
Depleting the Ozone: Distinguishing the Differences
Lab Automation & Robotics
Integration, Robotics, and Automation Ads By Google

Featured ContentCollaboration and Knowledge
Briefing On: Collaboration and Knowledge: Increasing Productivity in Life Sciences
SDMS Assists in 21 CFR Part II Compliance
Find out how a biopharmaceutical company dramatically improved their ability to control validated spreadsheets with Waters NuGenesis Scientific Data Management System (SDMS).
Beyond Genome
Systems Biology Briefing On
Global Gene Expression of Major Depression
Global Gene Expression of Major Depression - Reveals regulated Spermine/Spermidine N1-acetyltransferase (SAT) gene expression associated with a genetic polymorphism


Effective collaboration and knowledge sharing can speed efforts to discover, develop, and bring important biomedical products to patients. This compendium of articles by Bio-IT World editors looks at new collaboration technologies and how to effectively use them in the bench-to-bedside journey.

DOWNLOAD NOW
DOWNLOAD BUSINESS CASE STUDY Bio-IT World’s Editor In Chief, Kevin Davies, has aggregated key findings from the Systems Biology track at Beyond Genome and provided additional editorial from Bio-IT World archives. Beyond Genome and Bio-IT World (both Cambridge Healthtech Institute companies) have had an extensive focus on the growth of Systems Biology. We think you will find this latest summary considerably adds to your knowledge of the field.

DOWNLOAD NOW This white paper examines the expression levels of genes on microarrays using the BioExpress® System and Genesis Enterprise System® Software in post-mortem cortical regions from subjects who died by suicide with and without major depression versus a group of controls. SAT was identified as a potential candidate mediating the risk for suicide, whose expression may be differentially regulated as a consequence of a polymorphic variant of the SAT342 locus.

DOWNLOAD NOW

Featured EventsDiscovery on Target - October 23 - 27 - Boston, MA
2006 Genomes, Medicine and the Environment - October 16 - 18 - Hilton Head, SC
Storage Networking World - October 30 - November 2 - Olrando , FL
Would you like to see your conference or event listed here? Contact gina_bajenaru@bio-itworld.com for more information.

Sponsored LinksLasers Medical
Travel Nursing
Free Webinar from Accelrys: Enabling Multiscale Solutions for Nanomedicine
Gartner Predicts 2006: Collaboration Comes of Age, Key Findings and Recommendations About Collaboration
Genetic Immunization
Faster and Easier Compliance with PTC's Arbortext SPL Solution
ClinPartners enables emerging CROs to launch clinical trials efficiently
Would you like to see your message listed here? Contact Jeffrey Hyman at jeffrey_hyman@bio-itworld.com for more information.

The CHI NetworkCambridge Healthtech Institute| Beyond Genome | Bio-IT World | Biomarker World Congress | Chadvisors | Discovery On Target | Health-IT World | Life Sciences Conference + Expo | Molecular Medicine Tri-Conference| PEG Summit | PharmaDD| PharmaWeek | World Pharmaceutical Congress |

For reprints and/or copyright permission, please contact RMS, 1808 Colonial Village Lane, Lancaster, PA; (717) 399-1900 ext 100 or via email to bio-itworld@reprintbuyer.com.

National Medical Associations

American Medical Association
Web sites: http://www.ama-assn.org/ama/pub/category/2498.html, http://www.ama-assn.org/ama/pub/category/2558.html
Code of Ethics: http://www.ama-assn.org/ama/pub/category/2498.html
Contact: ceja@ama-assn.org, ife@ama-assn.org

FYI - There is going to be a BBC radio documentary on GDNF - being produced right now. We are working on having a possible meeting with Amgen expanded to an international meeting. Work continues behind the scenes and we have gained some additional European support.

PDF and Pipeline are also working on meetings to be held in a month or so to protect all stakeholders in clinical trials.

Paula

Dear Paula,
We that can feel for those that have neurodegenerative disease, we have more integrity in our shakey lil fingers, than the real rats behind the scenes
at Amgen, it upsets me, all I can do is pray that we do not have to suffer
much longer...

ive been on most recent gdnf trial- i think we should compare notes xxx

toridee,

Welcome to the forum, but I am sorry to say that lou_lou died several years ago.

See: lou_lou died - aka lavenderlou

I'm sure that the rest of us will be interested to know about your experiences.

John